Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO)
Evaluating the Use of Stereotactic Radiation Therapy Prior to Neoadjuvant Chemotherapy for High-risk Breast Carcinoma (a SIGNAL Series Clinical Trial): Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO Trial)
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
This NA trial investigates High-Risk Cancer and Locally Advanced Breast Cancer and is currently ongoing. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting NA
-
Apr 2025 — Feb 2026 [monthly]
Active Not Recruiting NA
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Recruiting NA
-
Sep 2024 — Jan 2025 [monthly]
Recruiting NA
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Recruiting NA
-
May 2023 — Feb 2024 [monthly]
Recruiting NA
-
Sep 2021 — May 2023 [monthly]
Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Not Yet Recruiting NA
-
Jul 2019 — Jul 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
For direct contact, visit the study record on ClinicalTrials.gov .